TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lungwena Child Nutrition Intervention Study 3, LCNI-3. A Single-Centre Intervention Trial in Rural Malawi, Testing the Anthropometric and Health Benefits of Provision of Ready to - Use - Therapeutic Food RUTF as a Complementary Food
Brief Summary: This study tests the hypothesis that infants receiving fortified spread as a complementary food for one year grow better and do not become malnourished as often as infants who are provided with maize-soy flour for complementary porridge.


Options:
A: Arm Label: fortified extruded rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fortified extruded rice | Intervention Type: DIETARY_SUPPLEMENT; Name: fortified extruded rice; Assigned to Arm(s): fortified extruded rice
B: Arm Label: Dietary supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Corn Soya Blend+ | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn Soya Blend+; Assigned to Arm(s): Dietary supplement
C: Arm Label: Fortified Yoghurt; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fortified Yoghurt | Arm Label: Yoghurt; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Yoghurt | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified Yoghurt; Assigned to Arm(s): Fortified Yoghurt | Intervention Type: DIETARY_SUPPLEMENT; Name: Yoghurt; Assigned to Arm(s): Yoghurt
D: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lungwena Child Nutrition Intervention Study 3, LCNI-3. A Single-Centre Intervention Trial in Rural Malawi, Testing the Anthropometric and Health Benefits of Provision of Ready to - Use - Therapeutic Food RUTF as a Complementary Food
Brief Summary: This study tests the hypothesis that infants receiving fortified spread as a complementary food for one year grow better and do not become malnourished as often as infants who are provided with maize-soy flour for complementary porridge.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A
B: Arm Label: Soy/peanut fortified spread; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy/peanut fortified spread | Arm Label: Milk fortified corn/soy blend; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Milk fortified corn/soy blend | Arm Label: Supplementary Plumpy®; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Supplementary Plumpy® | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy/peanut fortified spread; Assigned to Arm(s): Soy/peanut fortified spread | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk fortified corn/soy blend; Assigned to Arm(s): Milk fortified corn/soy blend | Intervention Type: DIETARY_SUPPLEMENT; Name: Supplementary Plumpy®; Assigned to Arm(s): Supplementary Plumpy®
C: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A
D: Arm Label: RUSF (500kcal/day) and cash transfer; Type: N/A; Interventions: N/A | Arm Label: Super Cereal Plus (SC+); Type: N/A; Interventions: N/A | Arm Label: RUSF; Type: N/A; Interventions: N/A | Arm Label: RUSF (250kcal/day) and cash transfer; Type: N/A; Interventions: N/A | Arm Label: SC+ and cash transfer; Type: N/A; Interventions: N/A | Arm Label: SC+ and household ration; Type: N/A; Interventions: N/A | Arm Label: Cash transfer; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin
Brief Summary: The purpose of this study is to examine whether treatment of pregnant Malawian women with repeated doses of sulfadoxine-pyrimethamine and azithromycin antibiotics will prevent preterm deliveries and result in other health benefits both for the mother and the foetus/newborn.


Options:
A: Arm Label: Daily TS + Monthly DP pregnancy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS) | Arm Label: Daily TS + DP Placebo pregnancy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS) | Intervention Type: DRUG; Name: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS); Assigned to Arm(s): Daily TS + Monthly DP pregnancy | Intervention Type: DRUG; Name: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS); Assigned to Arm(s): Daily TS + DP Placebo pregnancy
B: Arm Label: Mefloquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine | Arm Label: Sulphadoxine-Pyrimethamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-Pyrimethamine | Intervention Type: DRUG; Name: Mefloquine; Assigned to Arm(s): Mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-Pyrimethamine; Assigned to Arm(s): Sulphadoxine-Pyrimethamine
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine treatment twice during pregnancy | Arm Label: Monthly SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine at 4-week intervals | Arm Label: AZI-SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine treatment twice during pregnancy; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine at 4-week intervals; Assigned to Arm(s): Monthly SP | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice; Assigned to Arm(s): AZI-SP
D: Arm Label: IPTp-DP; Type: EXPERIMENTAL; Interventions: Drug: IPTp-DP | Arm Label: ISTp-DP; Type: EXPERIMENTAL; Interventions: Drug: ISTp-DP | Arm Label: IPTp-SP; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPTp-SP | Intervention Type: DRUG; Name: IPTp-SP; Assigned to Arm(s): IPTp-SP | Intervention Type: DRUG; Name: IPTp-DP; Assigned to Arm(s): IPTp-DP | Intervention Type: DRUG; Name: ISTp-DP; Assigned to Arm(s): ISTp-DP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin
Brief Summary: The purpose of this study is to examine whether treatment of pregnant Malawian women with repeated doses of sulfadoxine-pyrimethamine and azithromycin antibiotics will prevent preterm deliveries and result in other health benefits both for the mother and the foetus/newborn.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine treatment twice during pregnancy | Arm Label: Monthly SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine at 4-week intervals | Arm Label: AZI-SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine treatment twice during pregnancy; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine at 4-week intervals; Assigned to Arm(s): Monthly SP | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice; Assigned to Arm(s): AZI-SP

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Panic Disorder
Brief Summary: This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning including the extinction of fear. Participants will be randomly assigned (like flipping a coin) to receive either DCS or a placebo in addition to CBT.


Options:
A: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: Placebo | Arm Label: D-Cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: D-Cycloserine | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): D-Cycloserine, Sugar Pill | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill
B: Arm Label: Cognitive Behavioral Group Therapy + D-Cycloserine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: D-Cycloserine | Arm Label: Cognitive Behavioral Group Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy (CBGT), Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy (CBGT); Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine, Cognitive Behavioral Group Therapy + Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): Cognitive Behavioral Group Therapy + D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cognitive Behavioral Group Therapy + Placebo
C: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): N/A
D: Arm Label: D-cycloserine plus exposure therapy; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine, Behavioral: Exposure therapy | Arm Label: Placebo plus exposure therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Exposure therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus exposure therapy | Intervention Type: BEHAVIORAL; Name: Exposure therapy; Assigned to Arm(s): D-cycloserine plus exposure therapy, Placebo plus exposure therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus exposure therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy/Safety of Transdermal Patches Delivering Testosterone in Menopausal Women With Low Libido Not Receiving Estrogen Therapy
Brief Summary: This study is designed to evaluate the efficacy and safety of 2 doses of the transdermal testosterone patch in naturally or surgically menopausal women with low libido who are not receiving systemic estrogen or estrogen progestin therapy.


Options:
A: Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Testosterone (transdermal patches) | Intervention Type: DRUG; Name: Testosterone (transdermal patches); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo patch; Assigned to Arm(s): 1
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: dehydroepiandrosterone | Intervention Type: DRUG; Name: dehydroepiandrosterone; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy
Brief Summary: Malaria in pregnancy is potentially fatal to both the mother and the foetus particularly in the primigravidae. Implementation of appropriate control and preventive measures is challenged by the fact that malaria infection in pregnancy is often asymptomatic and parasitized red blood cells sequestrated in the placental microcirculation may not be detectable in the peripheral blood. In addition, the widespread prevalence of parasites resistant to chloroquine and sulphadoxine-pyrimethamine (SP) and, the safety concerns about newer antimalarials, poverty and inadequate supply have made antimalarial treatment options available to pregnant women very limited. These have necessitated an urgent search for alternative safe and efficacious treatment options for pregnant women. The objective of this study is to assess the efficacy, safety and tolerability of four antimalarial treatment options in rural Ghana within a programme setting.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chemoprophylaxis With Sulfadoxine-pyrimethamine to Prevent Recurrence of Severe Anaemia in Gambian Children Aged 3 Months to 9 Years
Brief Summary: Severe anaemia is a frequent cause of admission to hospitals in tropical Africa and about 10% of such children die. In endemic countries, anaemia has multiple causes such as nutritional deficiencies, infections and haemoglobinopathies. However, Plasmodium falciparum infection is believed to be the major contributory factor to the aetiology of severe anaemia. Severe anaemia is usually treated by blood transfusion although transfusion carries the attendant risk of transmission of HIV and other blood-borne infections. Thus, there is a need to explore novel strategies to reduce the incidence of severe anaemia in high-risk groups such as children with suboptimal haemoglobin levels because these children are at increased risk of developing severe anaemia if they develop a malaria infection before their haemoglobin level has normalized. Therefore, it is proposed to study whether monthly chemoprophylaxis with sulphadoxine/pyrimethamine (S/P) given during malaria transmission season can protect Gambian children from developing severe anaemia. After receiving treatment from the hospital, 1200 children admitted to the hospital with a haematocrit of less than 21% were randomised to receive either monthly S/P or placebo during the rest of the malaria transmission season. Morbidity was monitored throughout the rainy season. Study subjects were seen at the end of the dry season to document morbidity and mortality.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder
Brief Summary: This is a randomised trial comparing cognitive therapy and supportive therapy administered along one year in borderline personality disorder. The follow-up is one year after treatments end.

The therapists were the same in the two groups. Patients received one session a week during six months and one session every two weeks during the next six months


Options:
A: Arm Label: VHS group; Type: EXPERIMENTAL; Interventions: Behavioral: the volitional help sheet | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: the volitional help sheet; Assigned to Arm(s): VHS group
B: Arm Label: BI 1358894 5mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 25mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 75mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 125mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1358894; Assigned to Arm(s): BI 1358894 125mg, BI 1358894 25mg, BI 1358894 5mg, BI 1358894 75mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
D: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder
Brief Summary: This is a randomised trial comparing cognitive therapy and supportive therapy administered along one year in borderline personality disorder. The follow-up is one year after treatments end.

The therapists were the same in the two groups. Patients received one session a week during six months and one session every two weeks during the next six months


Options:
A: Arm Label: short-term dynamic therapy; Type: EXPERIMENTAL; Interventions: Behavioral: short-term dynamic therapy | Arm Label: long-term dynamic therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: long-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: short-term dynamic therapy; Assigned to Arm(s): short-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: long-term dynamic therapy; Assigned to Arm(s): long-term dynamic therapy
B: Arm Label: Dynamic Cognitive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dynamic Cognitive Intervention Group | Arm Label: No Additional Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dynamic Cognitive Intervention Group; Assigned to Arm(s): Dynamic Cognitive Intervention Group
C: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A
D: Arm Label: dynamic deconstructive psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychodynamic Therapy | Arm Label: optimized community care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimized Community Care | Intervention Type: BEHAVIORAL; Name: Psychodynamic Therapy; Assigned to Arm(s): dynamic deconstructive psychotherapy | Intervention Type: BEHAVIORAL; Name: Optimized Community Care; Assigned to Arm(s): optimized community care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder
Brief Summary: This is a randomised trial comparing cognitive therapy and supportive therapy administered along one year in borderline personality disorder. The follow-up is one year after treatments end.

The therapists were the same in the two groups. Patients received one session a week during six months and one session every two weeks during the next six months


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A
B: Arm Label: Follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Follow up | Arm Label: Usual Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Follow up; Assigned to Arm(s): Follow up
C: Arm Label: STEPPS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Systems Training for Emotional Predictability and Problem Solving (STEPPS) | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: Systems Training for Emotional Predictability and Problem Solving (STEPPS); Assigned to Arm(s): STEPPS | Intervention Type: BEHAVIORAL; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment as Usual
D: Arm Label: Group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Manualized Therapy | Arm Label: Control Group; Type: OTHER; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Manualized Therapy; Assigned to Arm(s): Group therapy | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Control Group

Answer: A